{"gene":"CDK4","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1994,"finding":"CDK4 (PSK-J3) and CDK6 (PLSTIRE) associate specifically with cyclin D1, forming a distinct subset of CDK complexes. In squamous carcinoma cells with amplified CCND1, cyclin D1 associates specifically with CDK4 and CDK6, while in diploid fibroblasts CDK2 and CDK5 can also co-precipitate with cyclin D1.","method":"Co-immunoprecipitation from tumor cell lines and diploid fibroblasts","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP in multiple cell types, replicated across cell line and primary cell contexts","pmids":["8302605"],"is_preprint":false},{"year":1994,"finding":"Assembly of cyclin D-CDK4 holoenzymes requires both subunit co-expression and serum stimulation in mammalian cells; phosphorylation of CDK4 on Thr172 by a CDK-activating kinase (CAK) is required for catalytic activity but assembly can proceed without this modification. CDK4 mutants that cannot be phosphorylated by CAK remain catalytically inactive.","method":"Baculovirus co-expression in Sf9 cells, in vitro kinase assays, site-directed mutagenesis of Thr172","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, clearly establishes activation mechanism","pmids":["8139570"],"is_preprint":false},{"year":1993,"finding":"CDK4 gene is located on human chromosome 12q13 and is co-amplified with MDM2 and GLI in osteosarcoma and rhabdomyosarcoma cell lines, leading to overexpression of CDK4 mRNA and protein without mutations in the coding sequence.","method":"FISH, Southern blot copy number analysis, Northern blot, nucleotide sequencing","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (FISH, Southern, Northern, sequencing) in a single study","pmids":["8221695"],"is_preprint":false},{"year":2006,"finding":"CDK4 forms a stable ternary complex with the Hsp90 molecular chaperone and the cochaperone adaptor Cdc37; the stoichiometry and 3D structure of this complex were determined by single-particle electron microscopy, showing Cdc37 bridges CDK4 and Hsp90, and CDK4 conformational changes are coupled to the Hsp90 ATPase cycle.","method":"Complex purification, native mass spectrometry, single-particle electron microscopy, comparison with Hsp90 crystal structure","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural determination by EM with stoichiometry by MS, single lab but multiple orthogonal methods","pmids":["16949366"],"is_preprint":false},{"year":2000,"finding":"c-MYC transcriptionally activates CDK4 expression through four highly conserved c-MYC binding sites in the CDK4 promoter; c-MYC-deficient cells show delayed cell-cycle progression associated with reduced CDK4 induction, and ectopic CDK4 expression partially rescues this growth defect.","method":"Serial analysis of gene expression (SAGE), promoter analysis, ectopic expression rescue in c-MYC-deficient cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — promoter binding analysis, loss-of-function with defined phenotypic readout, rescue experiment","pmids":["10688915"],"is_preprint":false},{"year":2001,"finding":"The CDK4 R24C mutation, which renders CDK4 insensitive to INK4 inhibitors including p16INK4a, is sufficient to cause melanoma susceptibility in knock-in mice upon carcinogenic treatment; these tumors do not harbor p19ARF/p53 pathway mutations, establishing a specific role for the p16INK4a/CDK4/Rb pathway in melanoma.","method":"CDK4 R24C knock-in mouse model, carcinogenic treatment, tumor molecular analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knock-in model with defined molecular pathway, replicated with additional INK4 knockout mice","pmids":["11606789"],"is_preprint":false},{"year":2005,"finding":"CDK4 promotes adipogenesis through activation of PPARgamma; CDK4 knockout mouse embryonic fibroblasts show reduced adipogenic potential while activating CDK4 mutations increase it. CDK4 effects extend beyond differentiation control to adipocyte function through PPARgamma activation.","method":"CDK4 knockout and CDK4 R24C knock-in mouse embryonic fibroblasts, adipogenic differentiation assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function and gain-of-function with defined phenotypic readout in primary cells","pmids":["16213226"],"is_preprint":false},{"year":2009,"finding":"CDK4 activates the CDK4-pRB-E2F1 pathway in pancreatic beta cells to regulate insulin secretion; CDK4 is activated by glucose via the insulin pathway, leading to E2F1 activation and transcriptional upregulation of Kir6.2 (a K-ATP channel subunit), thereby controlling glucose-induced insulin secretion. CDK4 inhibition or E2F1 knockout reduces Kir6.2 expression and impairs insulin secretion.","method":"Chromatin immunoprecipitation, genetic knockouts (CDK4-/-, E2f1-/-) in mice, rescue of Kir6.2 expression, glucose tolerance tests","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP from tissues, multiple genetic models, functional phenotype, rescue experiment","pmids":["19597485"],"is_preprint":false},{"year":2015,"finding":"CDK4 is an essential insulin effector in adipocytes; insulin activates the CCND3-CDK4 complex, which phosphorylates IRS2 at Ser388, creating a positive feedback loop maintaining adipocyte insulin signaling. CDK4-deficient mice show impaired lipogenesis and increased lipolysis, while CDK4 R24C hyperactive mice show the opposite. CDK4 deficiency impairs insulin signaling globally in white adipose tissue.","method":"Global kinome analysis, in vivo and in vitro phosphorylation assays, CDK4 knockout and R24C knock-in mice, IRS2 mutagenesis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay identifying substrate (IRS2 Ser388), multiple genetic models, global kinome analysis","pmids":["26657864"],"is_preprint":false},{"year":2017,"finding":"CDK4 promotes anaerobic glycolysis and represses fatty acid oxidation by directly phosphorylating and inhibiting AMPKα2. Expression of non-phosphorylatable AMPKα2 mutants or CDK4 inhibition increases fatty acid oxidation in mouse embryonic fibroblasts and myotubes. CDK4-deficient mice show increased oxidative metabolism and exercise capacity.","method":"In vitro kinase assay, site-directed mutagenesis of AMPKα2, CDK4 knockout mice, metabolic flux measurements","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro phosphorylation assay, mutagenesis, genetic model with defined phenotype","pmids":["29053957"],"is_preprint":false},{"year":2017,"finding":"CyclinD1-CDK4/6 complexes directly phosphorylate CDC25A on Ser40 during G1 phase in vitro and in cells, and this phosphorylation (along with Ser88) decreases CDC25A stability in a βTrCP-dependent manner, creating a negative feedback loop controlling G1/S transition.","method":"In vitro kinase assay, cell cycle synchronization, site-directed mutagenesis of Ser40, proteasome inhibitor experiments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, cell-based validation, single lab","pmids":["28192398"],"is_preprint":false},{"year":2017,"finding":"CDK4/6 inhibition suppresses proliferation of regulatory T cells and activates tumor cell expression of endogenous retroviral elements, increasing intracellular double-stranded RNA and stimulating type III interferon production. Both effects are associated with reduced activity of the E2F target DNMT1 (DNA methyltransferase 1), thereby enhancing tumor antigen presentation and cytotoxic T-cell clearance.","method":"Mouse tumor models (breast carcinoma and other solid tumors), transcriptomic analysis of clinical biopsies, mechanistic cell-based assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mouse models, clinical transcriptomic validation, mechanistic pathway identification with defined molecular target","pmids":["28813415"],"is_preprint":false},{"year":2019,"finding":"CDK4 phosphorylates the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. CDK4 also directly regulates lysosomal function and is essential for lysosomal degradation; CDK4 inhibition or knockout causes accumulation of undigested material in lysosomes, impairs autophagic flux, and induces cancer cell senescence.","method":"Pharmacological CDK4 inhibition, genetic CDK4 inactivation, in vitro phosphorylation assays, lysosomal function assays, xenograft models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro phosphorylation of FLCN, genetic and pharmacological inactivation, lysosomal assays, in vivo validation","pmids":["31395606"],"is_preprint":false},{"year":2020,"finding":"CyclinD-CDK4/6 directly binds and phosphorylates TSC2 on Ser1217 and Ser1452, activating mTORC1. CDK4/6 inhibition leads to a rapid, TSC2-dependent reduction of mTORC1 activity in multiple human and mouse cell lines. This mechanism couples cell growth (via mTORC1) with cell-cycle progression (via E2F).","method":"In vitro kinase assay, co-immunoprecipitation, pharmacological CDK4/6 inhibition in multiple cell lines, TSC2 loss-of-function rescue experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation identifying TSC2 as substrate, Co-IP demonstrating binding, genetic epistasis with TSC2 knockout","pmids":["32294430"],"is_preprint":false},{"year":2020,"finding":"CDK4/6 interact with and directly phosphorylate TFEB and TFE3 transcription factors in the nucleus, promoting their nuclear export and thereby inactivating them. During the cell cycle, lysosome numbers increase in S and G2/M phases when cyclin D turnover diminishes CDK4/6 activity, linking cell-cycle position to lysosome biogenesis.","method":"Co-immunoprecipitation, in vitro kinase assay, genetic CDK4/6 inactivation, subcellular localization studies, cell cycle synchronization","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation of TFEB/TFE3, Co-IP, subcellular localization with functional consequence","pmids":["32662822"],"is_preprint":false},{"year":2020,"finding":"CDK4 inhibition suppresses homologous recombination proteins required for recovery from chromosomal damage induced by taxanes, enabling sequential CDK4/6 inhibitor treatment after taxanes to prevent cellular proliferation in pancreatic ductal adenocarcinoma.","method":"Cell-based assays, patient-derived xenografts, genetically engineered mouse models (Kras G12V/Cdkn2a-null), Western blot analysis of HR protein levels","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological inhibition with mechanistic pathway identification (HR proteins), multiple model systems","pmids":["32109375"],"is_preprint":false},{"year":2021,"finding":"CDK4 activity sets the target cell size required for p38 MAPK inactivation and cell-cycle progression in a size checkpoint mechanism; CDK4 and p38 cooperate analogously to a thermostat, where p38 senses size irregularities and CDK4 sets the target size.","method":"Cell size measurements, CDK4 inhibition, genetic manipulation, cell cycle analysis","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic CDK4 manipulation with defined phenotypic readout, single lab","pmids":["34022133"],"is_preprint":false},{"year":2007,"finding":"CDK4 can extend the replicative lifespan of human diploid fibroblasts through kinase-dependent, p16INK4a-independent mechanisms; catalytically inactive CDK4 cannot extend lifespan, indicating effects depend on phosphorylation of substrates other than sequestration of CDK inhibitors. p16INK4a deficiency and CDK4 overexpression have additive effects on replicative lifespan.","method":"Overexpression of wild-type and catalytically inactive CDK4 in HDFs with INK4a mutations or repression, replicative lifespan assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — catalytic-dead mutant separates kinase-dependent from sequestration mechanisms, multiple genetic backgrounds tested","pmids":["17420273"],"is_preprint":false},{"year":2006,"finding":"CDK4 T-loop phosphorylation at Thr172 is a specific, determining target for cell cycle control by extracellular factors; this phosphorylation is regulated in CDK4 but not CDK6, indicating CDK4-activating kinase activity may be distinctly controlled for CDK4.","method":"Biochemical analysis of CDK4 activation states, comparison with CDK6","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — review paper summarizing own experimental findings, single lab","pmids":["17092340"],"is_preprint":false},{"year":2018,"finding":"CDK4 and CyclinD1 physically associate with p53-MDM2 complexes; CDK4 inhibition attenuates p53-responsive gene induction by reducing RNA Polymerase II recruitment to p53 target gene promoters (without reducing p53 binding or histone acetylation), revealing a role for CDK4/CyclinD1 in sustaining p53 transcriptional activity.","method":"Co-immunoprecipitation, siRNA knockdown, CDK4 inhibition, chromatin immunoprecipitation, gene expression analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying physical association, ChIP demonstrating mechanism at promoter level, single lab","pmids":["30206211"],"is_preprint":false},{"year":2018,"finding":"CDK4/6 phosphorylates EZH2 in keratinocytes, triggering methylation-induced activation of STAT3, which then induces IκBζ, a key proinflammatory transcription factor required for cytokine synthesis in psoriasis. Pharmacological or genetic inhibition of CDK4/6 abrogates this proinflammatory signaling.","method":"Genetic and pharmacological CDK4/6 inhibition in keratinocytes and mouse models, pathway analysis, topical drug application in psoriasis mouse models","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological CDK4/6 inhibition with defined downstream pathway (CDK4/6→EZH2→STAT3→IκBζ), in vivo validation","pmids":["32701505"],"is_preprint":false},{"year":2013,"finding":"CDK4 knockdown abrogates centrosome amplification and binucleation in HER2+ breast cancer cells; CDK4 and Nek2 are molecularly connected (protein levels of Nek2 diminish upon CDK4 knockdown and vice versa), and CDK4 controls cytokinesis fidelity upstream of Nek2.","method":"shRNA knockdown of CDK4 in HER2+ breast cancer cell lines, centrosome and binucleation quantification, Western blot for Nek2","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean loss-of-function with specific phenotypic readout, single lab, Nek2 connection by correlation only","pmids":["23776583"],"is_preprint":false},{"year":2023,"finding":"Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide bond between CDK4 C135 and cyclin D C7/8 that inhibits kinase activity, decreases RB phosphorylation, and induces cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, and this disulfide is reduced (CDK4 hyperactive) in pulmonary arterial hypertension patient tissue.","method":"Site-directed mutagenesis, tandem mass spectrometry, in vitro kinase assays, redox-dead knock-in mouse model, disease tissue analysis","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis, mass spectrometry identifying modification sites, in vitro kinase assay, transgenic mouse validation","pmids":["37955182"],"is_preprint":false},{"year":2014,"finding":"CDK4 inhibition combined with doxorubicin decreases colony formation and increases apoptosis in breast cancer cells; CDK4-mediated phosphorylation negatively regulates Smad3, and a Smad3 construct resistant to CDK4 phosphorylation (5M) phenocopies CDK4 inhibition by decreasing colony formation and altering apoptotic protein expression including survivin and XIAP.","method":"Smad3 phosphorylation-resistant mutant expression, CDK4 inhibitor treatment, apoptosis assays, 3D Matrigel colony assay","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mutagenesis approach identifying Smad3 as functional CDK4 substrate, single lab, limited mechanistic detail","pmids":["25006666"],"is_preprint":false},{"year":2025,"finding":"HR+ breast cancer cells are highly dependent on CDK4 but not CDK6 for proliferation; human bone marrow-derived cells rely primarily on CDK6 (not CDK4) for hematopoiesis, explaining the hematologic toxicity of dual CDK4/6 inhibitors. A CDK4-selective inhibitor (atirmociclib) reduces neutrophil suppression while maintaining antitumor activity.","method":"CDK4-selective inhibitor development, pharmacological comparison, cell line dependency studies, in vivo efficacy and toxicity studies","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and cell biology approaches distinguishing CDK4 vs CDK6 dependencies, multiple cell types","pmids":["40068598"],"is_preprint":false}],"current_model":"CDK4 is a serine/threonine kinase that, when assembled with D-type cyclins and activated by CAK-mediated phosphorylation at Thr172, phosphorylates RB to drive G1-to-S phase cell-cycle progression; beyond this canonical role, CDK4 directly phosphorylates substrates including TSC2 (activating mTORC1), AMPKα2 (repressing fatty acid oxidation), IRS2 (sustaining insulin signaling in adipocytes), FLCN (regulating lysosomal mTORC1 recruitment), TFEB/TFE3 (controlling lysosome biogenesis), EZH2 (triggering proinflammatory STAT3 signaling), and CDC25A (regulating its stability); CDK4 activity is regulated by cyclin D availability, Hsp90-Cdc37 chaperone association, CAK-dependent Thr172 phosphorylation, INK4 inhibitor binding (which is abrogated by the oncogenic R24C mutation), and a novel reversible disulfide bond at C135 that inhibits kinase activity under oxidative conditions."},"narrative":{"mechanistic_narrative":"CDK4 is a serine/threonine protein kinase that couples mitogenic signals to G1-to-S cell-cycle progression and to a broad program of cellular metabolism, growth, and lysosome control. It assembles specifically with D-type cyclins into holoenzymes whose catalytic activity additionally requires CAK-mediated phosphorylation of Thr172 — assembly can occur without this modification, but Thr172-deficient mutants remain inactive [PMID:8302605, PMID:8139570, PMID:17092340]. Holoenzyme maturation is supported by a ternary chaperone complex in which Cdc37 bridges CDK4 and Hsp90, coupling CDK4 conformation to the Hsp90 ATPase cycle [PMID:16949366]. Beyond phosphorylating RB to drive E2F-dependent transcription, active CDK4 directly phosphorylates a diverse substrate set: CDC25A on Ser40 to promote its βTrCP-dependent turnover as a G1/S negative feedback loop [PMID:28192398], TSC2 (Ser1217/Ser1452) and FLCN to activate and spatially control mTORC1 [PMID:31395606, PMID:32294430], TFEB/TFE3 to drive their nuclear export and thereby gate lysosome biogenesis to cell-cycle position [PMID:32662822], AMPKα2 to repress fatty acid oxidation and favor glycolysis [PMID:29053957], and IRS2 (Ser388) within a CCND3-CDK4 insulin feedback loop in adipocytes [PMID:26657864]. Through these substrates and an E2F1-dependent transcriptional arm, CDK4 governs adipogenesis via PPARγ, glucose-stimulated insulin secretion via Kir6.2, replicative lifespan, lysosomal degradation/autophagic flux, and cell-size checkpoint control [PMID:16213226, PMID:19597485, PMID:17420273, PMID:31395606, PMID:34022133]. CDK4 activity is constrained by INK4 inhibitor binding — abrogated by the oncogenic, melanoma-causing R24C mutation [PMID:11606789] — and by a reversible oxidant-induced disulfide between CDK4 Cys135 and cyclin D that inhibits the kinase under oxidative conditions and is lost (hyperactivating CDK4) in pulmonary arterial hypertension tissue [PMID:37955182]. CDK4 is amplified or transcriptionally upregulated (by c-MYC) in tumors, and HR+ breast cancers depend selectively on CDK4 over CDK6 [PMID:8221695, PMID:10688915, PMID:40068598].","teleology":[{"year":1993,"claim":"Established that CDK4 is a genuine oncogenic target by showing its locus is amplified in tumors, raising it as a driver of dysregulated proliferation.","evidence":"FISH, copy-number Southern, Northern, and sequencing in osteosarcoma/rhabdomyosarcoma lines","pmids":["8221695"],"confidence":"High","gaps":["Did not define the kinase's biochemical activity or substrates","Coding sequence unmutated, leaving functional consequence of overexpression unresolved at the time"]},{"year":1994,"claim":"Defined the partner specificity of CDK4 by showing it associates preferentially with cyclin D1, establishing the cyclin D-CDK4 holoenzyme as a distinct CDK class.","evidence":"Reciprocal co-immunoprecipitation in tumor lines and diploid fibroblasts","pmids":["8302605"],"confidence":"High","gaps":["Did not establish activation requirements","Cell-type differences in cyclin D partners not mechanistically explained"]},{"year":1994,"claim":"Resolved how the holoenzyme becomes catalytically competent, separating assembly from activation by identifying CAK phosphorylation of Thr172 as the activating step.","evidence":"Baculovirus co-expression in Sf9 cells, in vitro kinase assays, Thr172 mutagenesis","pmids":["8139570"],"confidence":"High","gaps":["Identity of the physiological CAK left open","Did not address upstream control of Thr172 by extracellular signals"]},{"year":2000,"claim":"Connected mitogenic transcription to CDK4 levels by showing c-MYC directly transactivates the CDK4 promoter, explaining how growth signals raise CDK4 abundance.","evidence":"SAGE, promoter analysis, ectopic-expression rescue in c-MYC-deficient cells","pmids":["10688915"],"confidence":"High","gaps":["Only partial rescue of the growth defect by CDK4","Other c-MYC targets contributing to the phenotype not excluded"]},{"year":2006,"claim":"Provided the structural basis for CDK4 maturation by determining the Hsp90-Cdc37-CDK4 ternary complex architecture, linking chaperoning to the kinase's conformational cycle.","evidence":"Complex purification, native MS, single-particle EM versus Hsp90 crystal structure","pmids":["16949366"],"confidence":"High","gaps":["Functional consequence of chaperone disruption on cell-cycle output not quantified","How chaperoning intersects with cyclin loading unresolved"]},{"year":2006,"claim":"Argued that Thr172 phosphorylation, not assembly, is the rate-limiting and signal-responsive node specific to CDK4 versus CDK6.","evidence":"Biochemical analysis of activation states comparing CDK4 and CDK6 (review of own data)","pmids":["17092340"],"confidence":"Medium","gaps":["Review-level summary of single-lab data","Distinct CAK activity for CDK4 not molecularly identified"]},{"year":2001,"claim":"Demonstrated causality between CDK4 escape from INK4 inhibition and cancer by showing the INK4-insensitive R24C mutation drives melanoma in vivo.","evidence":"CDK4 R24C knock-in mice with carcinogen treatment and tumor molecular analysis","pmids":["11606789"],"confidence":"High","gaps":["Tissue selectivity for melanoma not explained","Downstream substrate(s) mediating tumorigenesis not pinpointed"]},{"year":2005,"claim":"Extended CDK4 function beyond proliferation to differentiation by showing it promotes adipogenesis through PPARγ.","evidence":"CDK4 knockout and R24C knock-in MEFs in adipogenic differentiation assays","pmids":["16213226"],"confidence":"High","gaps":["Whether PPARγ is a direct CDK4 substrate not established","Kinase-dependence of the effect not separated from scaffolding"]},{"year":2007,"claim":"Showed CDK4 governs replicative lifespan through its kinase activity rather than mere inhibitor sequestration, implying substrates beyond RB.","evidence":"Wild-type versus catalytically inactive CDK4 overexpression in HDFs across INK4a backgrounds","pmids":["17420273"],"confidence":"High","gaps":["The relevant non-RB substrates not identified in this study","Mechanism additive with p16 loss not dissected"]},{"year":2009,"claim":"Linked CDK4 to systemic glucose physiology by defining a glucose-CDK4-pRB-E2F1 axis controlling Kir6.2 and insulin secretion in beta cells.","evidence":"ChIP, CDK4-/- and E2f1-/- mice, Kir6.2 rescue, glucose tolerance tests","pmids":["19597485"],"confidence":"High","gaps":["Direct CDK4 phosphorylation events upstream of E2F1 in this context not detailed","Crosstalk with insulin-pathway activation of CDK4 partially defined"]},{"year":2015,"claim":"Identified IRS2 Ser388 as a direct CDK4 substrate, establishing a CCND3-CDK4 positive feedback loop sustaining adipocyte insulin signaling.","evidence":"Global kinome analysis, in vivo/in vitro phosphorylation, CDK4 KO and R24C mice, IRS2 mutagenesis","pmids":["26657864"],"confidence":"High","gaps":["Generalizability of IRS2 phosphorylation beyond adipose tissue unclear","Quantitative contribution to whole-body insulin sensitivity not isolated"]},{"year":2017,"claim":"Defined a metabolic substrate by showing CDK4 directly phosphorylates and inhibits AMPKα2, shifting cells toward glycolysis and away from fatty acid oxidation.","evidence":"In vitro kinase assay, AMPKα2 mutagenesis, CDK4 KO mice, metabolic flux measurements","pmids":["29053957"],"confidence":"High","gaps":["Phosphosite on AMPKα2 not specified here","Interplay with the canonical AMPK kinases not addressed"]},{"year":2017,"claim":"Revealed a cell-cycle feedback substrate by showing cyclin D-CDK4/6 phosphorylates CDC25A on Ser40 to drive its βTrCP-dependent degradation at G1/S.","evidence":"In vitro kinase assay, synchronization, Ser40 mutagenesis, proteasome inhibition","pmids":["28192398"],"confidence":"High","gaps":["Single-lab finding","Quantitative impact on G1/S timing not modeled"]},{"year":2017,"claim":"Uncovered an immunologic consequence of CDK4/6 inhibition: derepression of endogenous retroviral elements and type III interferon via reduced E2F-target DNMT1, enhancing antitumor immunity.","evidence":"Mouse tumor models, clinical transcriptomics, mechanistic cell assays","pmids":["28813415"],"confidence":"High","gaps":["CDK4 versus CDK6 contribution not separated","Direct kinase substrates upstream of DNMT1 not pinpointed"]},{"year":2019,"claim":"Tied CDK4 to lysosomal mTORC1 signaling by showing it phosphorylates FLCN and is required for lysosomal degradation and autophagic flux.","evidence":"Pharmacologic/genetic CDK4 inactivation, in vitro phosphorylation, lysosomal assays, xenografts","pmids":["31395606"],"confidence":"High","gaps":["FLCN phosphosite(s) not enumerated here","Whether lysosomal defect is fully FLCN-dependent unresolved"]},{"year":2020,"claim":"Established CDK4/6 as a direct mTORC1 activator by identifying TSC2 (Ser1217/Ser1452) as a substrate, coupling cell growth to cell-cycle progression.","evidence":"In vitro kinase assay, Co-IP, CDK4/6 inhibition across cell lines, TSC2 loss-of-function rescue","pmids":["32294430"],"confidence":"High","gaps":["Relative contribution of TSC2 versus FLCN to mTORC1 control not resolved","In vivo physiological relevance not fully tested"]},{"year":2020,"claim":"Linked cell-cycle position to organelle biogenesis by showing CDK4/6 phosphorylates TFEB/TFE3 to drive their nuclear export and suppress lysosome biogenesis.","evidence":"Co-IP, in vitro kinase assay, genetic CDK4/6 inactivation, localization, synchronization","pmids":["32662822"],"confidence":"High","gaps":["TFEB/TFE3 phosphosites not specified","Single-lab finding"]},{"year":2020,"claim":"Identified a DNA-repair vulnerability whereby CDK4 inhibition suppresses homologous recombination proteins, rationalizing sequential taxane-then-CDK4/6i therapy in pancreatic cancer.","evidence":"Cell assays, PDX, Kras/Cdkn2a-null GEMMs, Western blot of HR proteins","pmids":["32109375"],"confidence":"Medium","gaps":["Direct CDK4 substrates among HR factors not identified","Transcriptional versus post-translational mechanism of HR suppression unclear"]},{"year":2021,"claim":"Positioned CDK4 within a cell-size checkpoint, setting the target size at which p38 MAPK is inactivated to permit cell-cycle progression.","evidence":"Cell size measurements, CDK4 inhibition, genetic manipulation, cell-cycle analysis","pmids":["34022133"],"confidence":"Medium","gaps":["Molecular link between CDK4 activity and p38 not defined","Single-lab finding"]},{"year":2018,"claim":"Showed CDK4/cyclin D1 sustains p53 transcriptional output by promoting RNA Pol II recruitment to p53 target promoters, adding a non-RB role at the chromatin level.","evidence":"Co-IP, siRNA, CDK4 inhibition, ChIP, gene expression analysis","pmids":["30206211"],"confidence":"Medium","gaps":["Direct substrate within the transcription machinery not identified","Single-lab finding"]},{"year":2018,"claim":"Defined a proinflammatory CDK4/6→EZH2→STAT3→IκBζ axis in keratinocytes relevant to psoriasis, broadening CDK4 function into inflammation.","evidence":"Genetic/pharmacologic CDK4/6 inhibition, pathway analysis, psoriasis mouse models","pmids":["32701505"],"confidence":"Medium","gaps":["EZH2 phosphosite not specified","CDK4 versus CDK6 contribution not separated"]},{"year":2013,"claim":"Implicated CDK4 in cytokinesis fidelity by showing its knockdown abrogates centrosome amplification and binucleation, with a reciprocal protein-level link to Nek2.","evidence":"shRNA knockdown in HER2+ breast cells, centrosome/binucleation quantification, Nek2 Western blot","pmids":["23776583"],"confidence":"Medium","gaps":["Nek2 connection is correlative, not a defined biochemical interaction","Single-lab finding"]},{"year":2014,"claim":"Proposed Smad3 as a functional CDK4 substrate whose negative regulation modulates apoptosis (survivin/XIAP) and colony formation in breast cancer.","evidence":"Phospho-resistant Smad3 mutant, CDK4 inhibition, apoptosis and 3D colony assays","pmids":["25006666"],"confidence":"Medium","gaps":["Limited mechanistic detail on direct phosphorylation","Single-lab finding"]},{"year":2023,"claim":"Discovered a redox switch controlling CDK4: a reversible Cys135-cyclin D disulfide inhibits the kinase under oxidation, with loss of the disulfide hyperactivating CDK4 in pulmonary arterial hypertension.","evidence":"Mutagenesis, tandem MS, in vitro kinase assays, redox-dead knock-in mice, disease tissue","pmids":["37955182"],"confidence":"High","gaps":["Physiological oxidant generating the disulfide not defined","How redox status integrates with Thr172 activation unresolved"]},{"year":2025,"claim":"Distinguished CDK4 from CDK6 dependencies, showing HR+ breast cancers need CDK4 while hematopoiesis relies on CDK6, motivating CDK4-selective inhibition to spare neutrophils.","evidence":"CDK4-selective inhibitor (atirmociclib), dependency studies, in vivo efficacy/toxicity","pmids":["40068598"],"confidence":"Medium","gaps":["Molecular basis of tissue-specific CDK4 versus CDK6 reliance not fully defined","Long-term clinical durability not addressed"]},{"year":null,"claim":"How CDK4's many direct substrates (TSC2, FLCN, TFEB/TFE3, AMPKα2, IRS2, EZH2, Smad3) are selected and prioritized in a given cell state, and how Thr172, chaperone loading, and the Cys135 redox switch are integrated to set kinase output, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model coordinating substrate choice with activation inputs","Physiological signals controlling the redox switch unknown","Tissue-specific substrate hierarchies not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,8,9,10,12,13,14]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,8,9,10]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[14,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1,10,16]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,9,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,13,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,5,22,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,20]}],"complexes":["Cyclin D-CDK4 holoenzyme","Hsp90-Cdc37-CDK4 chaperone complex"],"partners":["CCND1","CCND3","CDC37","HSP90","MDM2","TP53","FLCN","TSC2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11802","full_name":"Cyclin-dependent kinase 4","aliases":["Cell division protein kinase 4","PSK-J3"],"length_aa":303,"mass_kda":33.7,"function":"Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex","subcellular_location":"Cytoplasm; Nucleus; Nucleus membrane","url":"https://www.uniprot.org/uniprotkb/P11802/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDK4","classification":"Common Essential","n_dependent_lines":778,"n_total_lines":1208,"dependency_fraction":0.6440397350993378},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000135446","cell_line_id":"CID001149","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"CDKN2C","stoichiometry":10.0},{"gene":"ANKRD52","stoichiometry":0.2},{"gene":"DSG1","stoichiometry":0.2},{"gene":"CDKN2A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001149","total_profiled":1310},"omim":[{"mim_id":"621507","title":"MICROCEPHALY 31, PRIMARY, AUTOSOMAL RECESSIVE; MCPH31","url":"https://www.omim.org/entry/621507"},{"mim_id":"620524","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 16; DCAF16","url":"https://www.omim.org/entry/620524"},{"mim_id":"617891","title":"ZINC FINGER PROTEIN 655; ZNF655","url":"https://www.omim.org/entry/617891"},{"mim_id":"615134","title":"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9","url":"https://www.omim.org/entry/615134"},{"mim_id":"614084","title":"WEE1 HOMOLOG 2; WEE2","url":"https://www.omim.org/entry/614084"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDK4"},"hgnc":{"alias_symbol":["PSK-J3"],"prev_symbol":[]},"alphafold":{"accession":"P11802","domains":[{"cath_id":"3.30.200.20","chopping":"7-93","consensus_level":"high","plddt":82.7385,"start":7,"end":93},{"cath_id":"1.10.510.10","chopping":"98-156_177-294","consensus_level":"high","plddt":95.5041,"start":98,"end":294}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11802","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11802-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11802-F1-predicted_aligned_error_v6.png","plddt_mean":86.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDK4","jax_strain_url":"https://www.jax.org/strain/search?query=CDK4"},"sequence":{"accession":"P11802","fasta_url":"https://rest.uniprot.org/uniprotkb/P11802.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11802/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11802"}},"corpus_meta":[{"pmid":"28813415","id":"PMC_28813415","title":"CDK4/6 inhibition triggers anti-tumour immunity.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28813415","citation_count":1193,"is_preprint":false},{"pmid":"27030077","id":"PMC_27030077","title":"Treating cancer with selective CDK4/6 inhibitors.","date":"2016","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27030077","citation_count":904,"is_preprint":false},{"pmid":"26658964","id":"PMC_26658964","title":"Targeting CDK4 and CDK6: From Discovery to Therapy.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26658964","citation_count":744,"is_preprint":false},{"pmid":"10688915","id":"PMC_10688915","title":"Identification of CDK4 as a target of c-MYC.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10688915","citation_count":408,"is_preprint":false},{"pmid":"35304604","id":"PMC_35304604","title":"Targeting CDK4 and CDK6 in cancer.","date":"2022","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35304604","citation_count":404,"is_preprint":false},{"pmid":"30061045","id":"PMC_30061045","title":"CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30061045","citation_count":378,"is_preprint":false},{"pmid":"35025636","id":"PMC_35025636","title":"CDK4 and CDK6 kinases: From basic science to cancer therapy.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35025636","citation_count":362,"is_preprint":false},{"pmid":"8221695","id":"PMC_8221695","title":"Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8221695","citation_count":362,"is_preprint":false},{"pmid":"27017286","id":"PMC_27017286","title":"Targeting CDK4/6 in patients with cancer.","date":"2016","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27017286","citation_count":360,"is_preprint":false},{"pmid":"32289274","id":"PMC_32289274","title":"Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.","date":"2020","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/32289274","citation_count":320,"is_preprint":false},{"pmid":"8302605","id":"PMC_8302605","title":"CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8302605","citation_count":291,"is_preprint":false},{"pmid":"8139570","id":"PMC_8139570","title":"Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8139570","citation_count":275,"is_preprint":false},{"pmid":"16949366","id":"PMC_16949366","title":"Structure of an Hsp90-Cdc37-Cdk4 complex.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16949366","citation_count":248,"is_preprint":false},{"pmid":"24795392","id":"PMC_24795392","title":"Molecular pathways: CDK4 inhibitors for cancer therapy.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24795392","citation_count":201,"is_preprint":false},{"pmid":"32723562","id":"PMC_32723562","title":"Cyclin D-CDK4/6 functions in cancer.","date":"2020","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32723562","citation_count":170,"is_preprint":false},{"pmid":"32899866","id":"PMC_32899866","title":"Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32899866","citation_count":146,"is_preprint":false},{"pmid":"16213226","id":"PMC_16213226","title":"Cdk4 promotes adipogenesis through PPARgamma activation.","date":"2005","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16213226","citation_count":135,"is_preprint":false},{"pmid":"30959874","id":"PMC_30959874","title":"Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30959874","citation_count":129,"is_preprint":false},{"pmid":"11606789","id":"PMC_11606789","title":"Invasive melanoma in Cdk4-targeted mice.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11606789","citation_count":128,"is_preprint":false},{"pmid":"32541838","id":"PMC_32541838","title":"Senescence as a therapeutically relevant response to CDK4/6 inhibitors.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32541838","citation_count":125,"is_preprint":false},{"pmid":"32357912","id":"PMC_32357912","title":"The application and prospect of CDK4/6 inhibitors in malignant solid tumors.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32357912","citation_count":122,"is_preprint":false},{"pmid":"34327137","id":"PMC_34327137","title":"Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34327137","citation_count":121,"is_preprint":false},{"pmid":"32109375","id":"PMC_32109375","title":"CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.","date":"2020","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/32109375","citation_count":119,"is_preprint":false},{"pmid":"32294430","id":"PMC_32294430","title":"Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32294430","citation_count":111,"is_preprint":false},{"pmid":"19597485","id":"PMC_19597485","title":"The CDK4-pRB-E2F1 pathway controls insulin secretion.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19597485","citation_count":111,"is_preprint":false},{"pmid":"25876993","id":"PMC_25876993","title":"The Role of CDK4/6 Inhibition in Breast Cancer.","date":"2015","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/25876993","citation_count":106,"is_preprint":false},{"pmid":"19383288","id":"PMC_19383288","title":"Mice thrive without Cdk4 and Cdk2.","date":"2007","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383288","citation_count":97,"is_preprint":false},{"pmid":"29739788","id":"PMC_29739788","title":"MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29739788","citation_count":92,"is_preprint":false},{"pmid":"28629371","id":"PMC_28629371","title":"Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28629371","citation_count":89,"is_preprint":false},{"pmid":"35982377","id":"PMC_35982377","title":"Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.","date":"2022","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35982377","citation_count":88,"is_preprint":false},{"pmid":"32662822","id":"PMC_32662822","title":"CDK4/6 regulate lysosome biogenesis through TFEB/TFE3.","date":"2020","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32662822","citation_count":88,"is_preprint":false},{"pmid":"32068118","id":"PMC_32068118","title":"A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32068118","citation_count":87,"is_preprint":false},{"pmid":"7738717","id":"PMC_7738717","title":"MDM2 and CDK4 gene amplification in Ewing's sarcoma.","date":"1995","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7738717","citation_count":87,"is_preprint":false},{"pmid":"21477379","id":"PMC_21477379","title":"Elevated expression of CDK4 in lung cancer.","date":"2011","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21477379","citation_count":84,"is_preprint":false},{"pmid":"25810375","id":"PMC_25810375","title":"CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25810375","citation_count":80,"is_preprint":false},{"pmid":"9036865","id":"PMC_9036865","title":"p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9036865","citation_count":79,"is_preprint":false},{"pmid":"27986745","id":"PMC_27986745","title":"Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27986745","citation_count":78,"is_preprint":false},{"pmid":"30397176","id":"PMC_30397176","title":"A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30397176","citation_count":77,"is_preprint":false},{"pmid":"30084835","id":"PMC_30084835","title":"Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30084835","citation_count":75,"is_preprint":false},{"pmid":"17092340","id":"PMC_17092340","title":"Regulation of CDK4.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17092340","citation_count":63,"is_preprint":false},{"pmid":"36153348","id":"PMC_36153348","title":"Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.","date":"2022","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36153348","citation_count":62,"is_preprint":false},{"pmid":"33364954","id":"PMC_33364954","title":"Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33364954","citation_count":61,"is_preprint":false},{"pmid":"26657864","id":"PMC_26657864","title":"CDK4 is an essential insulin effector in adipocytes.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26657864","citation_count":61,"is_preprint":false},{"pmid":"30125344","id":"PMC_30125344","title":"JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30125344","citation_count":60,"is_preprint":false},{"pmid":"32933570","id":"PMC_32933570","title":"CDK4/6 inhibitors: a novel strategy for tumor radiosensitization.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32933570","citation_count":59,"is_preprint":false},{"pmid":"29053957","id":"PMC_29053957","title":"CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29053957","citation_count":59,"is_preprint":false},{"pmid":"29935900","id":"PMC_29935900","title":"Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.","date":"2017","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29935900","citation_count":58,"is_preprint":false},{"pmid":"17420273","id":"PMC_17420273","title":"CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17420273","citation_count":55,"is_preprint":false},{"pmid":"29452249","id":"PMC_29452249","title":"Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29452249","citation_count":54,"is_preprint":false},{"pmid":"31307887","id":"PMC_31307887","title":"Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.","date":"2019","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31307887","citation_count":52,"is_preprint":false},{"pmid":"10884881","id":"PMC_10884881","title":"Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.","date":"2000","source":"British journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/10884881","citation_count":52,"is_preprint":false},{"pmid":"30224338","id":"PMC_30224338","title":"To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30224338","citation_count":51,"is_preprint":false},{"pmid":"40068598","id":"PMC_40068598","title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.","date":"2025","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/40068598","citation_count":50,"is_preprint":false},{"pmid":"32546660","id":"PMC_32546660","title":"Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32546660","citation_count":49,"is_preprint":false},{"pmid":"10390011","id":"PMC_10390011","title":"Mutation testing in melanoma families: INK4A, CDK4 and INK4D.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10390011","citation_count":49,"is_preprint":false},{"pmid":"35479560","id":"PMC_35479560","title":"CDK4/6 inhibitors: a brief overview and prospective research directions.","date":"2021","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35479560","citation_count":48,"is_preprint":false},{"pmid":"32701505","id":"PMC_32701505","title":"The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32701505","citation_count":44,"is_preprint":false},{"pmid":"8275715","id":"PMC_8275715","title":"Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes.","date":"1994","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8275715","citation_count":43,"is_preprint":false},{"pmid":"28325261","id":"PMC_28325261","title":"CDK4/6 inhibitors in HER2-positive breast cancer.","date":"2017","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28325261","citation_count":41,"is_preprint":false},{"pmid":"32523378","id":"PMC_32523378","title":"Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32523378","citation_count":41,"is_preprint":false},{"pmid":"30858922","id":"PMC_30858922","title":"The interplay of CDK4 and CDK6 in melanoma.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30858922","citation_count":40,"is_preprint":false},{"pmid":"23776583","id":"PMC_23776583","title":"Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23776583","citation_count":39,"is_preprint":false},{"pmid":"37875500","id":"PMC_37875500","title":"Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37875500","citation_count":39,"is_preprint":false},{"pmid":"31555743","id":"PMC_31555743","title":"SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31555743","citation_count":38,"is_preprint":false},{"pmid":"38277141","id":"PMC_38277141","title":"Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38277141","citation_count":37,"is_preprint":false},{"pmid":"39930131","id":"PMC_39930131","title":"Targeting CDK4/6 in breast cancer.","date":"2025","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39930131","citation_count":37,"is_preprint":false},{"pmid":"28192398","id":"PMC_28192398","title":"CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28192398","citation_count":37,"is_preprint":false},{"pmid":"31395606","id":"PMC_31395606","title":"CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31395606","citation_count":37,"is_preprint":false},{"pmid":"34022133","id":"PMC_34022133","title":"Cell size homeostasis is maintained by CDK4-dependent activation of p38 MAPK.","date":"2021","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/34022133","citation_count":37,"is_preprint":false},{"pmid":"32855282","id":"PMC_32855282","title":"Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32855282","citation_count":37,"is_preprint":false},{"pmid":"26053278","id":"PMC_26053278","title":"CDK4/6 inhibitors in breast cancer.","date":"2015","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/26053278","citation_count":36,"is_preprint":false},{"pmid":"35327487","id":"PMC_35327487","title":"Targeting CDK4/6 for Anticancer Therapy.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35327487","citation_count":34,"is_preprint":false},{"pmid":"11063650","id":"PMC_11063650","title":"Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.","date":"2000","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11063650","citation_count":34,"is_preprint":false},{"pmid":"27391794","id":"PMC_27391794","title":"Roles of Cell Cyle Regulators Cyclin D1, CDK4, and p53 in Knee Osteoarthritis.","date":"2016","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/27391794","citation_count":34,"is_preprint":false},{"pmid":"33255177","id":"PMC_33255177","title":"CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment.","date":"2020","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33255177","citation_count":33,"is_preprint":false},{"pmid":"35444175","id":"PMC_35444175","title":"Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?","date":"2022","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35444175","citation_count":33,"is_preprint":false},{"pmid":"29392622","id":"PMC_29392622","title":"Clinical development of CDK4/6 inhibitor for breast cancer.","date":"2018","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/29392622","citation_count":31,"is_preprint":false},{"pmid":"30206211","id":"PMC_30206211","title":"CDK4 inhibition diminishes p53 activation by MDM2 antagonists.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30206211","citation_count":31,"is_preprint":false},{"pmid":"38424044","id":"PMC_38424044","title":"MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38424044","citation_count":30,"is_preprint":false},{"pmid":"35917168","id":"PMC_35917168","title":"Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.","date":"2022","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/35917168","citation_count":30,"is_preprint":false},{"pmid":"33803309","id":"PMC_33803309","title":"Development of CDK4/6 Inhibitors: A Five Years Update.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33803309","citation_count":30,"is_preprint":false},{"pmid":"25680902","id":"PMC_25680902","title":"MDM2 and CDK4 expression in periosteal osteosarcoma.","date":"2014","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25680902","citation_count":28,"is_preprint":false},{"pmid":"37276679","id":"PMC_37276679","title":"Development of PROTAC degrader probe of CDK4/6 based on DCAF16.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37276679","citation_count":28,"is_preprint":false},{"pmid":"26649278","id":"PMC_26649278","title":"CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26649278","citation_count":28,"is_preprint":false},{"pmid":"37182667","id":"PMC_37182667","title":"Immunomodulatory effects of CDK4/6 inhibitors.","date":"2023","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37182667","citation_count":27,"is_preprint":false},{"pmid":"36637424","id":"PMC_36637424","title":"SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36637424","citation_count":27,"is_preprint":false},{"pmid":"10325446","id":"PMC_10325446","title":"Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue.","date":"1999","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/10325446","citation_count":27,"is_preprint":false},{"pmid":"30359883","id":"PMC_30359883","title":"Targeting CDK4/6 pathways and beyond in breast cancer.","date":"2018","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/30359883","citation_count":26,"is_preprint":false},{"pmid":"36562384","id":"PMC_36562384","title":"Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion.","date":"2022","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36562384","citation_count":26,"is_preprint":false},{"pmid":"34087775","id":"PMC_34087775","title":"The role of CDK4/6 inhibitors in early breast cancer.","date":"2021","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/34087775","citation_count":26,"is_preprint":false},{"pmid":"28209757","id":"PMC_28209757","title":"CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28209757","citation_count":26,"is_preprint":false},{"pmid":"37955182","id":"PMC_37955182","title":"Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37955182","citation_count":25,"is_preprint":false},{"pmid":"33300617","id":"PMC_33300617","title":"How selective are clinical CDK4/6 inhibitors?","date":"2020","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33300617","citation_count":25,"is_preprint":false},{"pmid":"32712436","id":"PMC_32712436","title":"Getting under the skin: The role of CDK4/6 in melanomas.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32712436","citation_count":25,"is_preprint":false},{"pmid":"32026294","id":"PMC_32026294","title":"The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32026294","citation_count":25,"is_preprint":false},{"pmid":"39885369","id":"PMC_39885369","title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.","date":"2025","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39885369","citation_count":24,"is_preprint":false},{"pmid":"32430489","id":"PMC_32430489","title":"Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32430489","citation_count":24,"is_preprint":false},{"pmid":"25006666","id":"PMC_25006666","title":"CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25006666","citation_count":23,"is_preprint":false},{"pmid":"29194728","id":"PMC_29194728","title":"CDK4 expression in chordoma: A potential therapeutic target.","date":"2017","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/29194728","citation_count":22,"is_preprint":false},{"pmid":"38138549","id":"PMC_38138549","title":"Recent Progress in CDK4/6 Inhibitors and PROTACs.","date":"2023","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38138549","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44310,"output_tokens":6085,"usd":0.112102,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14965,"output_tokens":6868,"usd":0.123262,"stage2_stop_reason":"end_turn"},"total_usd":0.235364,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CDK4 (PSK-J3) and CDK6 (PLSTIRE) associate specifically with cyclin D1, forming a distinct subset of CDK complexes. In squamous carcinoma cells with amplified CCND1, cyclin D1 associates specifically with CDK4 and CDK6, while in diploid fibroblasts CDK2 and CDK5 can also co-precipitate with cyclin D1.\",\n      \"method\": \"Co-immunoprecipitation from tumor cell lines and diploid fibroblasts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP in multiple cell types, replicated across cell line and primary cell contexts\",\n      \"pmids\": [\"8302605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Assembly of cyclin D-CDK4 holoenzymes requires both subunit co-expression and serum stimulation in mammalian cells; phosphorylation of CDK4 on Thr172 by a CDK-activating kinase (CAK) is required for catalytic activity but assembly can proceed without this modification. CDK4 mutants that cannot be phosphorylated by CAK remain catalytically inactive.\",\n      \"method\": \"Baculovirus co-expression in Sf9 cells, in vitro kinase assays, site-directed mutagenesis of Thr172\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, clearly establishes activation mechanism\",\n      \"pmids\": [\"8139570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CDK4 gene is located on human chromosome 12q13 and is co-amplified with MDM2 and GLI in osteosarcoma and rhabdomyosarcoma cell lines, leading to overexpression of CDK4 mRNA and protein without mutations in the coding sequence.\",\n      \"method\": \"FISH, Southern blot copy number analysis, Northern blot, nucleotide sequencing\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (FISH, Southern, Northern, sequencing) in a single study\",\n      \"pmids\": [\"8221695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CDK4 forms a stable ternary complex with the Hsp90 molecular chaperone and the cochaperone adaptor Cdc37; the stoichiometry and 3D structure of this complex were determined by single-particle electron microscopy, showing Cdc37 bridges CDK4 and Hsp90, and CDK4 conformational changes are coupled to the Hsp90 ATPase cycle.\",\n      \"method\": \"Complex purification, native mass spectrometry, single-particle electron microscopy, comparison with Hsp90 crystal structure\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural determination by EM with stoichiometry by MS, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16949366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-MYC transcriptionally activates CDK4 expression through four highly conserved c-MYC binding sites in the CDK4 promoter; c-MYC-deficient cells show delayed cell-cycle progression associated with reduced CDK4 induction, and ectopic CDK4 expression partially rescues this growth defect.\",\n      \"method\": \"Serial analysis of gene expression (SAGE), promoter analysis, ectopic expression rescue in c-MYC-deficient cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding analysis, loss-of-function with defined phenotypic readout, rescue experiment\",\n      \"pmids\": [\"10688915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The CDK4 R24C mutation, which renders CDK4 insensitive to INK4 inhibitors including p16INK4a, is sufficient to cause melanoma susceptibility in knock-in mice upon carcinogenic treatment; these tumors do not harbor p19ARF/p53 pathway mutations, establishing a specific role for the p16INK4a/CDK4/Rb pathway in melanoma.\",\n      \"method\": \"CDK4 R24C knock-in mouse model, carcinogenic treatment, tumor molecular analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knock-in model with defined molecular pathway, replicated with additional INK4 knockout mice\",\n      \"pmids\": [\"11606789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CDK4 promotes adipogenesis through activation of PPARgamma; CDK4 knockout mouse embryonic fibroblasts show reduced adipogenic potential while activating CDK4 mutations increase it. CDK4 effects extend beyond differentiation control to adipocyte function through PPARgamma activation.\",\n      \"method\": \"CDK4 knockout and CDK4 R24C knock-in mouse embryonic fibroblasts, adipogenic differentiation assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function and gain-of-function with defined phenotypic readout in primary cells\",\n      \"pmids\": [\"16213226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CDK4 activates the CDK4-pRB-E2F1 pathway in pancreatic beta cells to regulate insulin secretion; CDK4 is activated by glucose via the insulin pathway, leading to E2F1 activation and transcriptional upregulation of Kir6.2 (a K-ATP channel subunit), thereby controlling glucose-induced insulin secretion. CDK4 inhibition or E2F1 knockout reduces Kir6.2 expression and impairs insulin secretion.\",\n      \"method\": \"Chromatin immunoprecipitation, genetic knockouts (CDK4-/-, E2f1-/-) in mice, rescue of Kir6.2 expression, glucose tolerance tests\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP from tissues, multiple genetic models, functional phenotype, rescue experiment\",\n      \"pmids\": [\"19597485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CDK4 is an essential insulin effector in adipocytes; insulin activates the CCND3-CDK4 complex, which phosphorylates IRS2 at Ser388, creating a positive feedback loop maintaining adipocyte insulin signaling. CDK4-deficient mice show impaired lipogenesis and increased lipolysis, while CDK4 R24C hyperactive mice show the opposite. CDK4 deficiency impairs insulin signaling globally in white adipose tissue.\",\n      \"method\": \"Global kinome analysis, in vivo and in vitro phosphorylation assays, CDK4 knockout and R24C knock-in mice, IRS2 mutagenesis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay identifying substrate (IRS2 Ser388), multiple genetic models, global kinome analysis\",\n      \"pmids\": [\"26657864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4 promotes anaerobic glycolysis and represses fatty acid oxidation by directly phosphorylating and inhibiting AMPKα2. Expression of non-phosphorylatable AMPKα2 mutants or CDK4 inhibition increases fatty acid oxidation in mouse embryonic fibroblasts and myotubes. CDK4-deficient mice show increased oxidative metabolism and exercise capacity.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis of AMPKα2, CDK4 knockout mice, metabolic flux measurements\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro phosphorylation assay, mutagenesis, genetic model with defined phenotype\",\n      \"pmids\": [\"29053957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CyclinD1-CDK4/6 complexes directly phosphorylate CDC25A on Ser40 during G1 phase in vitro and in cells, and this phosphorylation (along with Ser88) decreases CDC25A stability in a βTrCP-dependent manner, creating a negative feedback loop controlling G1/S transition.\",\n      \"method\": \"In vitro kinase assay, cell cycle synchronization, site-directed mutagenesis of Ser40, proteasome inhibitor experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, cell-based validation, single lab\",\n      \"pmids\": [\"28192398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4/6 inhibition suppresses proliferation of regulatory T cells and activates tumor cell expression of endogenous retroviral elements, increasing intracellular double-stranded RNA and stimulating type III interferon production. Both effects are associated with reduced activity of the E2F target DNMT1 (DNA methyltransferase 1), thereby enhancing tumor antigen presentation and cytotoxic T-cell clearance.\",\n      \"method\": \"Mouse tumor models (breast carcinoma and other solid tumors), transcriptomic analysis of clinical biopsies, mechanistic cell-based assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mouse models, clinical transcriptomic validation, mechanistic pathway identification with defined molecular target\",\n      \"pmids\": [\"28813415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK4 phosphorylates the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. CDK4 also directly regulates lysosomal function and is essential for lysosomal degradation; CDK4 inhibition or knockout causes accumulation of undigested material in lysosomes, impairs autophagic flux, and induces cancer cell senescence.\",\n      \"method\": \"Pharmacological CDK4 inhibition, genetic CDK4 inactivation, in vitro phosphorylation assays, lysosomal function assays, xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro phosphorylation of FLCN, genetic and pharmacological inactivation, lysosomal assays, in vivo validation\",\n      \"pmids\": [\"31395606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CyclinD-CDK4/6 directly binds and phosphorylates TSC2 on Ser1217 and Ser1452, activating mTORC1. CDK4/6 inhibition leads to a rapid, TSC2-dependent reduction of mTORC1 activity in multiple human and mouse cell lines. This mechanism couples cell growth (via mTORC1) with cell-cycle progression (via E2F).\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, pharmacological CDK4/6 inhibition in multiple cell lines, TSC2 loss-of-function rescue experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation identifying TSC2 as substrate, Co-IP demonstrating binding, genetic epistasis with TSC2 knockout\",\n      \"pmids\": [\"32294430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4/6 interact with and directly phosphorylate TFEB and TFE3 transcription factors in the nucleus, promoting their nuclear export and thereby inactivating them. During the cell cycle, lysosome numbers increase in S and G2/M phases when cyclin D turnover diminishes CDK4/6 activity, linking cell-cycle position to lysosome biogenesis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, genetic CDK4/6 inactivation, subcellular localization studies, cell cycle synchronization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation of TFEB/TFE3, Co-IP, subcellular localization with functional consequence\",\n      \"pmids\": [\"32662822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4 inhibition suppresses homologous recombination proteins required for recovery from chromosomal damage induced by taxanes, enabling sequential CDK4/6 inhibitor treatment after taxanes to prevent cellular proliferation in pancreatic ductal adenocarcinoma.\",\n      \"method\": \"Cell-based assays, patient-derived xenografts, genetically engineered mouse models (Kras G12V/Cdkn2a-null), Western blot analysis of HR protein levels\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological inhibition with mechanistic pathway identification (HR proteins), multiple model systems\",\n      \"pmids\": [\"32109375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK4 activity sets the target cell size required for p38 MAPK inactivation and cell-cycle progression in a size checkpoint mechanism; CDK4 and p38 cooperate analogously to a thermostat, where p38 senses size irregularities and CDK4 sets the target size.\",\n      \"method\": \"Cell size measurements, CDK4 inhibition, genetic manipulation, cell cycle analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic CDK4 manipulation with defined phenotypic readout, single lab\",\n      \"pmids\": [\"34022133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CDK4 can extend the replicative lifespan of human diploid fibroblasts through kinase-dependent, p16INK4a-independent mechanisms; catalytically inactive CDK4 cannot extend lifespan, indicating effects depend on phosphorylation of substrates other than sequestration of CDK inhibitors. p16INK4a deficiency and CDK4 overexpression have additive effects on replicative lifespan.\",\n      \"method\": \"Overexpression of wild-type and catalytically inactive CDK4 in HDFs with INK4a mutations or repression, replicative lifespan assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic-dead mutant separates kinase-dependent from sequestration mechanisms, multiple genetic backgrounds tested\",\n      \"pmids\": [\"17420273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CDK4 T-loop phosphorylation at Thr172 is a specific, determining target for cell cycle control by extracellular factors; this phosphorylation is regulated in CDK4 but not CDK6, indicating CDK4-activating kinase activity may be distinctly controlled for CDK4.\",\n      \"method\": \"Biochemical analysis of CDK4 activation states, comparison with CDK6\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — review paper summarizing own experimental findings, single lab\",\n      \"pmids\": [\"17092340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK4 and CyclinD1 physically associate with p53-MDM2 complexes; CDK4 inhibition attenuates p53-responsive gene induction by reducing RNA Polymerase II recruitment to p53 target gene promoters (without reducing p53 binding or histone acetylation), revealing a role for CDK4/CyclinD1 in sustaining p53 transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, CDK4 inhibition, chromatin immunoprecipitation, gene expression analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying physical association, ChIP demonstrating mechanism at promoter level, single lab\",\n      \"pmids\": [\"30206211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK4/6 phosphorylates EZH2 in keratinocytes, triggering methylation-induced activation of STAT3, which then induces IκBζ, a key proinflammatory transcription factor required for cytokine synthesis in psoriasis. Pharmacological or genetic inhibition of CDK4/6 abrogates this proinflammatory signaling.\",\n      \"method\": \"Genetic and pharmacological CDK4/6 inhibition in keratinocytes and mouse models, pathway analysis, topical drug application in psoriasis mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological CDK4/6 inhibition with defined downstream pathway (CDK4/6→EZH2→STAT3→IκBζ), in vivo validation\",\n      \"pmids\": [\"32701505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK4 knockdown abrogates centrosome amplification and binucleation in HER2+ breast cancer cells; CDK4 and Nek2 are molecularly connected (protein levels of Nek2 diminish upon CDK4 knockdown and vice versa), and CDK4 controls cytokinesis fidelity upstream of Nek2.\",\n      \"method\": \"shRNA knockdown of CDK4 in HER2+ breast cancer cell lines, centrosome and binucleation quantification, Western blot for Nek2\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean loss-of-function with specific phenotypic readout, single lab, Nek2 connection by correlation only\",\n      \"pmids\": [\"23776583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide bond between CDK4 C135 and cyclin D C7/8 that inhibits kinase activity, decreases RB phosphorylation, and induces cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, and this disulfide is reduced (CDK4 hyperactive) in pulmonary arterial hypertension patient tissue.\",\n      \"method\": \"Site-directed mutagenesis, tandem mass spectrometry, in vitro kinase assays, redox-dead knock-in mouse model, disease tissue analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis, mass spectrometry identifying modification sites, in vitro kinase assay, transgenic mouse validation\",\n      \"pmids\": [\"37955182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CDK4 inhibition combined with doxorubicin decreases colony formation and increases apoptosis in breast cancer cells; CDK4-mediated phosphorylation negatively regulates Smad3, and a Smad3 construct resistant to CDK4 phosphorylation (5M) phenocopies CDK4 inhibition by decreasing colony formation and altering apoptotic protein expression including survivin and XIAP.\",\n      \"method\": \"Smad3 phosphorylation-resistant mutant expression, CDK4 inhibitor treatment, apoptosis assays, 3D Matrigel colony assay\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mutagenesis approach identifying Smad3 as functional CDK4 substrate, single lab, limited mechanistic detail\",\n      \"pmids\": [\"25006666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HR+ breast cancer cells are highly dependent on CDK4 but not CDK6 for proliferation; human bone marrow-derived cells rely primarily on CDK6 (not CDK4) for hematopoiesis, explaining the hematologic toxicity of dual CDK4/6 inhibitors. A CDK4-selective inhibitor (atirmociclib) reduces neutrophil suppression while maintaining antitumor activity.\",\n      \"method\": \"CDK4-selective inhibitor development, pharmacological comparison, cell line dependency studies, in vivo efficacy and toxicity studies\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and cell biology approaches distinguishing CDK4 vs CDK6 dependencies, multiple cell types\",\n      \"pmids\": [\"40068598\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK4 is a serine/threonine kinase that, when assembled with D-type cyclins and activated by CAK-mediated phosphorylation at Thr172, phosphorylates RB to drive G1-to-S phase cell-cycle progression; beyond this canonical role, CDK4 directly phosphorylates substrates including TSC2 (activating mTORC1), AMPKα2 (repressing fatty acid oxidation), IRS2 (sustaining insulin signaling in adipocytes), FLCN (regulating lysosomal mTORC1 recruitment), TFEB/TFE3 (controlling lysosome biogenesis), EZH2 (triggering proinflammatory STAT3 signaling), and CDC25A (regulating its stability); CDK4 activity is regulated by cyclin D availability, Hsp90-Cdc37 chaperone association, CAK-dependent Thr172 phosphorylation, INK4 inhibitor binding (which is abrogated by the oncogenic R24C mutation), and a novel reversible disulfide bond at C135 that inhibits kinase activity under oxidative conditions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDK4 is a serine/threonine protein kinase that couples mitogenic signals to G1-to-S cell-cycle progression and to a broad program of cellular metabolism, growth, and lysosome control. It assembles specifically with D-type cyclins into holoenzymes whose catalytic activity additionally requires CAK-mediated phosphorylation of Thr172 — assembly can occur without this modification, but Thr172-deficient mutants remain inactive [#0, #1, #18]. Holoenzyme maturation is supported by a ternary chaperone complex in which Cdc37 bridges CDK4 and Hsp90, coupling CDK4 conformation to the Hsp90 ATPase cycle [#3]. Beyond phosphorylating RB to drive E2F-dependent transcription, active CDK4 directly phosphorylates a diverse substrate set: CDC25A on Ser40 to promote its βTrCP-dependent turnover as a G1/S negative feedback loop [#10], TSC2 (Ser1217/Ser1452) and FLCN to activate and spatially control mTORC1 [#12, #13], TFEB/TFE3 to drive their nuclear export and thereby gate lysosome biogenesis to cell-cycle position [#14], AMPKα2 to repress fatty acid oxidation and favor glycolysis [#9], and IRS2 (Ser388) within a CCND3-CDK4 insulin feedback loop in adipocytes [#8]. Through these substrates and an E2F1-dependent transcriptional arm, CDK4 governs adipogenesis via PPARγ, glucose-stimulated insulin secretion via Kir6.2, replicative lifespan, lysosomal degradation/autophagic flux, and cell-size checkpoint control [#6, #7, #17, #12, #16]. CDK4 activity is constrained by INK4 inhibitor binding — abrogated by the oncogenic, melanoma-causing R24C mutation [#5] — and by a reversible oxidant-induced disulfide between CDK4 Cys135 and cyclin D that inhibits the kinase under oxidative conditions and is lost (hyperactivating CDK4) in pulmonary arterial hypertension tissue [#22]. CDK4 is amplified or transcriptionally upregulated (by c-MYC) in tumors, and HR+ breast cancers depend selectively on CDK4 over CDK6 [#2, #4, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that CDK4 is a genuine oncogenic target by showing its locus is amplified in tumors, raising it as a driver of dysregulated proliferation.\",\n      \"evidence\": \"FISH, copy-number Southern, Northern, and sequencing in osteosarcoma/rhabdomyosarcoma lines\",\n      \"pmids\": [\"8221695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the kinase's biochemical activity or substrates\", \"Coding sequence unmutated, leaving functional consequence of overexpression unresolved at the time\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined the partner specificity of CDK4 by showing it associates preferentially with cyclin D1, establishing the cyclin D-CDK4 holoenzyme as a distinct CDK class.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation in tumor lines and diploid fibroblasts\",\n      \"pmids\": [\"8302605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish activation requirements\", \"Cell-type differences in cyclin D partners not mechanistically explained\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Resolved how the holoenzyme becomes catalytically competent, separating assembly from activation by identifying CAK phosphorylation of Thr172 as the activating step.\",\n      \"evidence\": \"Baculovirus co-expression in Sf9 cells, in vitro kinase assays, Thr172 mutagenesis\",\n      \"pmids\": [\"8139570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the physiological CAK left open\", \"Did not address upstream control of Thr172 by extracellular signals\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected mitogenic transcription to CDK4 levels by showing c-MYC directly transactivates the CDK4 promoter, explaining how growth signals raise CDK4 abundance.\",\n      \"evidence\": \"SAGE, promoter analysis, ectopic-expression rescue in c-MYC-deficient cells\",\n      \"pmids\": [\"10688915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Only partial rescue of the growth defect by CDK4\", \"Other c-MYC targets contributing to the phenotype not excluded\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided the structural basis for CDK4 maturation by determining the Hsp90-Cdc37-CDK4 ternary complex architecture, linking chaperoning to the kinase's conformational cycle.\",\n      \"evidence\": \"Complex purification, native MS, single-particle EM versus Hsp90 crystal structure\",\n      \"pmids\": [\"16949366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of chaperone disruption on cell-cycle output not quantified\", \"How chaperoning intersects with cyclin loading unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Argued that Thr172 phosphorylation, not assembly, is the rate-limiting and signal-responsive node specific to CDK4 versus CDK6.\",\n      \"evidence\": \"Biochemical analysis of activation states comparing CDK4 and CDK6 (review of own data)\",\n      \"pmids\": [\"17092340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level summary of single-lab data\", \"Distinct CAK activity for CDK4 not molecularly identified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated causality between CDK4 escape from INK4 inhibition and cancer by showing the INK4-insensitive R24C mutation drives melanoma in vivo.\",\n      \"evidence\": \"CDK4 R24C knock-in mice with carcinogen treatment and tumor molecular analysis\",\n      \"pmids\": [\"11606789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue selectivity for melanoma not explained\", \"Downstream substrate(s) mediating tumorigenesis not pinpointed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended CDK4 function beyond proliferation to differentiation by showing it promotes adipogenesis through PPARγ.\",\n      \"evidence\": \"CDK4 knockout and R24C knock-in MEFs in adipogenic differentiation assays\",\n      \"pmids\": [\"16213226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PPARγ is a direct CDK4 substrate not established\", \"Kinase-dependence of the effect not separated from scaffolding\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed CDK4 governs replicative lifespan through its kinase activity rather than mere inhibitor sequestration, implying substrates beyond RB.\",\n      \"evidence\": \"Wild-type versus catalytically inactive CDK4 overexpression in HDFs across INK4a backgrounds\",\n      \"pmids\": [\"17420273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The relevant non-RB substrates not identified in this study\", \"Mechanism additive with p16 loss not dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked CDK4 to systemic glucose physiology by defining a glucose-CDK4-pRB-E2F1 axis controlling Kir6.2 and insulin secretion in beta cells.\",\n      \"evidence\": \"ChIP, CDK4-/- and E2f1-/- mice, Kir6.2 rescue, glucose tolerance tests\",\n      \"pmids\": [\"19597485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CDK4 phosphorylation events upstream of E2F1 in this context not detailed\", \"Crosstalk with insulin-pathway activation of CDK4 partially defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified IRS2 Ser388 as a direct CDK4 substrate, establishing a CCND3-CDK4 positive feedback loop sustaining adipocyte insulin signaling.\",\n      \"evidence\": \"Global kinome analysis, in vivo/in vitro phosphorylation, CDK4 KO and R24C mice, IRS2 mutagenesis\",\n      \"pmids\": [\"26657864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability of IRS2 phosphorylation beyond adipose tissue unclear\", \"Quantitative contribution to whole-body insulin sensitivity not isolated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a metabolic substrate by showing CDK4 directly phosphorylates and inhibits AMPKα2, shifting cells toward glycolysis and away from fatty acid oxidation.\",\n      \"evidence\": \"In vitro kinase assay, AMPKα2 mutagenesis, CDK4 KO mice, metabolic flux measurements\",\n      \"pmids\": [\"29053957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosite on AMPKα2 not specified here\", \"Interplay with the canonical AMPK kinases not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a cell-cycle feedback substrate by showing cyclin D-CDK4/6 phosphorylates CDC25A on Ser40 to drive its βTrCP-dependent degradation at G1/S.\",\n      \"evidence\": \"In vitro kinase assay, synchronization, Ser40 mutagenesis, proteasome inhibition\",\n      \"pmids\": [\"28192398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab finding\", \"Quantitative impact on G1/S timing not modeled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Uncovered an immunologic consequence of CDK4/6 inhibition: derepression of endogenous retroviral elements and type III interferon via reduced E2F-target DNMT1, enhancing antitumor immunity.\",\n      \"evidence\": \"Mouse tumor models, clinical transcriptomics, mechanistic cell assays\",\n      \"pmids\": [\"28813415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CDK4 versus CDK6 contribution not separated\", \"Direct kinase substrates upstream of DNMT1 not pinpointed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Tied CDK4 to lysosomal mTORC1 signaling by showing it phosphorylates FLCN and is required for lysosomal degradation and autophagic flux.\",\n      \"evidence\": \"Pharmacologic/genetic CDK4 inactivation, in vitro phosphorylation, lysosomal assays, xenografts\",\n      \"pmids\": [\"31395606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FLCN phosphosite(s) not enumerated here\", \"Whether lysosomal defect is fully FLCN-dependent unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established CDK4/6 as a direct mTORC1 activator by identifying TSC2 (Ser1217/Ser1452) as a substrate, coupling cell growth to cell-cycle progression.\",\n      \"evidence\": \"In vitro kinase assay, Co-IP, CDK4/6 inhibition across cell lines, TSC2 loss-of-function rescue\",\n      \"pmids\": [\"32294430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of TSC2 versus FLCN to mTORC1 control not resolved\", \"In vivo physiological relevance not fully tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked cell-cycle position to organelle biogenesis by showing CDK4/6 phosphorylates TFEB/TFE3 to drive their nuclear export and suppress lysosome biogenesis.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, genetic CDK4/6 inactivation, localization, synchronization\",\n      \"pmids\": [\"32662822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TFEB/TFE3 phosphosites not specified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a DNA-repair vulnerability whereby CDK4 inhibition suppresses homologous recombination proteins, rationalizing sequential taxane-then-CDK4/6i therapy in pancreatic cancer.\",\n      \"evidence\": \"Cell assays, PDX, Kras/Cdkn2a-null GEMMs, Western blot of HR proteins\",\n      \"pmids\": [\"32109375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CDK4 substrates among HR factors not identified\", \"Transcriptional versus post-translational mechanism of HR suppression unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Positioned CDK4 within a cell-size checkpoint, setting the target size at which p38 MAPK is inactivated to permit cell-cycle progression.\",\n      \"evidence\": \"Cell size measurements, CDK4 inhibition, genetic manipulation, cell-cycle analysis\",\n      \"pmids\": [\"34022133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between CDK4 activity and p38 not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed CDK4/cyclin D1 sustains p53 transcriptional output by promoting RNA Pol II recruitment to p53 target promoters, adding a non-RB role at the chromatin level.\",\n      \"evidence\": \"Co-IP, siRNA, CDK4 inhibition, ChIP, gene expression analysis\",\n      \"pmids\": [\"30206211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrate within the transcription machinery not identified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a proinflammatory CDK4/6→EZH2→STAT3→IκBζ axis in keratinocytes relevant to psoriasis, broadening CDK4 function into inflammation.\",\n      \"evidence\": \"Genetic/pharmacologic CDK4/6 inhibition, pathway analysis, psoriasis mouse models\",\n      \"pmids\": [\"32701505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"EZH2 phosphosite not specified\", \"CDK4 versus CDK6 contribution not separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Implicated CDK4 in cytokinesis fidelity by showing its knockdown abrogates centrosome amplification and binucleation, with a reciprocal protein-level link to Nek2.\",\n      \"evidence\": \"shRNA knockdown in HER2+ breast cells, centrosome/binucleation quantification, Nek2 Western blot\",\n      \"pmids\": [\"23776583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nek2 connection is correlative, not a defined biochemical interaction\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Proposed Smad3 as a functional CDK4 substrate whose negative regulation modulates apoptosis (survivin/XIAP) and colony formation in breast cancer.\",\n      \"evidence\": \"Phospho-resistant Smad3 mutant, CDK4 inhibition, apoptosis and 3D colony assays\",\n      \"pmids\": [\"25006666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited mechanistic detail on direct phosphorylation\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovered a redox switch controlling CDK4: a reversible Cys135-cyclin D disulfide inhibits the kinase under oxidation, with loss of the disulfide hyperactivating CDK4 in pulmonary arterial hypertension.\",\n      \"evidence\": \"Mutagenesis, tandem MS, in vitro kinase assays, redox-dead knock-in mice, disease tissue\",\n      \"pmids\": [\"37955182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological oxidant generating the disulfide not defined\", \"How redox status integrates with Thr172 activation unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Distinguished CDK4 from CDK6 dependencies, showing HR+ breast cancers need CDK4 while hematopoiesis relies on CDK6, motivating CDK4-selective inhibition to spare neutrophils.\",\n      \"evidence\": \"CDK4-selective inhibitor (atirmociclib), dependency studies, in vivo efficacy/toxicity\",\n      \"pmids\": [\"40068598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of tissue-specific CDK4 versus CDK6 reliance not fully defined\", \"Long-term clinical durability not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CDK4's many direct substrates (TSC2, FLCN, TFEB/TFE3, AMPKα2, IRS2, EZH2, Smad3) are selected and prioritized in a given cell state, and how Thr172, chaperone loading, and the Cys135 redox switch are integrated to set kinase output, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model coordinating substrate choice with activation inputs\", \"Physiological signals controlling the redox switch unknown\", \"Tissue-specific substrate hierarchies not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 8, 9, 10, 12, 13, 14]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 8, 9, 10]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [14, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1, 10, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 9, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 5, 22, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 20]}\n    ],\n    \"complexes\": [\"Cyclin D-CDK4 holoenzyme\", \"Hsp90-Cdc37-CDK4 chaperone complex\"],\n    \"partners\": [\"CCND1\", \"CCND3\", \"CDC37\", \"HSP90\", \"MDM2\", \"TP53\", \"FLCN\", \"TSC2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}